Obesity reviews: an official journal of the International Association for the Study of Obesity , 17 (10), 970976
Key points: In clinical trials, tirzepatide (Mounjaro) produced roughly double the average weight loss of liraglutide (Saxenda), though these were separate trials with different durations Tirzepatide at the 15 mg dose produced approximately 21% average weight loss over 72 weeks Liraglutide 3.0 mg produced approximately 8% average weight loss over 56 weeks Real-world data from Second Nature shows even greater results (22.1%) when tirzepatide is combined with behavioural support Side effects and tolerability Both medications share a similar side-effect profile, predominantly affecting the gastrointestinal tract
1 month supply
GF mice, naturally lacking SCFAs, show a compromised BBB, while introducing butyrate or butyrate-producing bacteria like Clostridium tyrobutyricum can improve BBB dysfunction in these mice (141)
While a late period may sometimes be an isolated incident, specific symptoms necessitate medical attention
I think not everyone can feel this
